Biotech firm Stellanova Therapeutics closes $15.5M Series A, names CEO

Houston-based biotechnology firm Stellanova Therapeutics raised $15.5 million to advance development of its cancer therapies. The Series A round was led by Houston-based Sporos Bioventures LLC, Stellanova announced June 3. Stellanova is developing therapies targeting the tumor microenvironment in order to treat cancers that are resistant to current therapies, the company said. Stellanova's lead clinical candidate is an antibody that targets DKK3, a factor promoting therapeutic resistance and…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news